Navigation Links
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022
Date:10/28/2013

BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents—Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences' idelalisib, Roche/Genentech/Chugai/Glycart's obinutuzumab, Celgene's Revlimid and Pfizer's Afinitor—together with the continued use of rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will fuel more than 6 percent annual growth in the non-Hodgkin's lymphoma (NHL) drug market. In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, sales will exceed $10 billion in 2022, with the kinase inhibitors ibrutinib and idelalisib comprising more than one-fifth of market share. These two agents will launch as treatments for multiple NHL subpopulations, and their use in combination with existing therapies, as well as monotherapies, will ensure that they will significantly add to the overall size of the market. The anticipated approval of Revlimid in the diffuse large B-cell lymphoma maintenance setting will also trigger significant market growth.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Non-Hodgkin's Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries' Treanda/Levact/Treakisym/Ribomustin, a cytotoxic chemotherapy that is becoming more and more entrenched in the treatment of NHL, will continue to experience an increase in use across most NHL subpopulations, but its sales will decline as a result of generic entry.

"New therapies entering the market will change the way NHL patients are treated by 2022," said Decision Resources Business Insights Analyst Dana Gheorghe, Ph.D. "Of particular interest are the entries of the kinase inhibitors ibrutinib and idelalisib, which are poised to have a tremendous impact on the treatment of NHL patients, especially those with relapsed/refractory chronic lymphocytic leukemia and follicular lymphoma, but also mantle cell lymphoma. The anticipated approval of obinutuzumab will also impact how some NHL patients are managed, as the drug has been shown to be more efficacious than rituximab in certain subpopulations."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
2. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
3. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
4. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
5. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
8. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
9. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
11. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):